



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.09
Trade Time:	6:30 PM ET 01/16/18
Change:	-0.03 ↓ (1.415%)
Day Range	2.00 - 2.15
52-Week Range	1.60 - 7.10
Volume	187,755

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [01/08/18
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018](#)
- [01/04/18
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer](#)
- [12/11/17
Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium](#)
- [11/09/17
Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference](#)
- [11/08/17
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- [02/24/17
Annual Report \(10-K\)](#)
- [02/24/17
Proxy Statement \(DEF 14A\)](#)
- [11/03/17
Quarterly Report \(10-Q\)](#)
- [08/04/17
Quarterly Report \(10-Q\)](#)
- [05/03/17
Quarterly Report \(10-Q\)](#)